Navigation Links
OncoGenex Pharmaceuticals to Participate in Panel Discussion on Novel Cancer Treatments at RBC Capital Markets Healthcare Conference
Date:2/28/2011

BOTHELL, Wash., and VANCOUVER, British Columbia, Feb. 28, 2011 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (Nasdaq: OGXI) announced today that Scott Cormack, OncoGenex's president and chief executive officer, will take part in a panel discussion on novel cancer treatments at the upcoming RBC Capital Markets Healthcare Conference. The panel discussion entitled, "Cancer Treatments: Under the Radar Unique Late-Stage Opportunities", will take place on Wednesday, March 2, 2011, at 9 a.m. (Eastern Time) in the Holmes I Room of the New York Palace Hotel, in New York City.

A live audio webcast of the panel discussion will be available on Investor Relations page of the OncoGenex website at www.oncogenex.com. A replay of the webcast will also be available on the Company's website for a period of 90 days.

About OncoGenex

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceuticals have entered a global collaboration and license agreement to develop and commercialize OncoGenex's lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer. The companies plan to begin Phase 3 development of custirsen in first-line treatment of advanced, unresectable non-small cell lung cancer in 2011. OGX-427 is in Phase 2 clinical development; SN2310 has completed a Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development. More information is available at

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. OncoGenex Expands Clinical Development of OGX-427 with a Phase 1 Clinical Trial in Bladder Cancer
2. Isis Pharmaceuticals to Receive $10 Million From OncoGenex License of OGX-011 to Teva
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
10. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
11. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  CytoSorbents Corporation (NASDAQ CM: ... CytoSorb® extracorporeal cytokine adsorber to reduce deadly inflammation ... receipt of $385,642, net of transaction costs, in ... Technology Business Tax Certificate Transfer Program sponsored by ...
(Date:1/23/2015)... Gem Pharmaceuticals announced today that the initial soft ... Company,s Phase 2 clinical trial.  This open-label study will ... GPX-150 (an investigational medication), in approximately 30 adults as ... Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO GPX-150 ...
(Date:1/23/2015)... 2015 Tianyin Pharmaceutical Inc. (NYSE Amex: ... development and sale of patented biopharmaceutical medicine, modernized traditional ... (API) today announced the business and development progress at ... 1. Following the September 2014 JCM application (No. 51268) ...
Breaking Medicine Technology:CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4
(Date:1/22/2015)... Weddingshe.com has added many trendy Champagne wedding dresses ... in the past three years. Today, the business announces a ... to the sales manager of the company, this is on ... This point can be reflected on the discounted wedding dresses ...
(Date:1/22/2015)... Payday lending practices in four southern states ... distress to the states that permit them, according to ... on Race and Wealth. , While they generate hundreds ... at the same time substantially depress economic activity, according ...
(Date:1/22/2015)... a famous dress online store for wedding dresses and other ... of wedding dresses , and launches a site-wide women’s dress ... on your big day; the wedding gown is the most ... find the most suitable wedding dress. Now, we are proud ...
(Date:1/22/2015)... VA (PRWEB) January 22, 2015 Step ... power at the Science Museum of Virginia. Wicked Plants, ... , Wicked Plants unearths 75 poisonous, carnivorous and diabolical ... through each room to uncover the biochemical, physical and ...
(Date:12/26/2014)... said that nothing makes a lady feel more feminine than ... shows its new selection of navy cocktail dresses , ... navy cocktail gowns are the cornerstones of the site’s cocktail ... dresses in bright neon colors can be dressed up or ...
Breaking Medicine News(10 mins):Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2Health News:Wicked Plants are taking over the Science Museum of Virginia 2Health News:UWDress.com Shows Its New Navy Cocktail Dresses For 2015 2
... 11, 2007 Physicians at UT Southwestern Medical Center are the ... small radioactive pellet, or seed, is implanted into a mass or ... surgical removal. , During the procedure, a radiologist uses a needle ... grain of rice, into the mass. Once lodged, surgeons use a ...
... Oct. 11, 2007 Dr. Beth Levine, professor ... division of infectious diseases at UT Southwestern Medical Center, ... today. , Dr. Levine is one of 15 new ... a philanthropic organization that promotes biomedical research. Her appointment ...
... 1999 Equity ... Incentive Plan, ... leading provider of state-of-the-art diagnostic and,digital imaging systems directed towards women,s ... that,Hologic stockholders vote "FOR" the Company,s proposed merger with Cytyc,Corporation (Nasdaq: ...
... Just released trial data show high acceptance of interactive ... system, two-thirds of patients prefer automated system, ... a developer,of advanced interactive voice response (IVR) solutions, today ... (IVRS) optimized,for use in the healthcare environment. CallAssure uses ...
... Step-by-Step Process and Provides Sample Appeal,Letter, WASHINGTON, Oct. ... peace of mind that they will have,access to the ... the medicine that,s prescribed by the doctor isn,t always,covered. ... need,to know what they can do about it., ...
... Quality of Health Care, PITTSBURGH, Oct. 11 ... select hospitals in Western Pennsylvania as part of ... line- associated bloodstream infections. Central lines are ... nutrition to critically ill patients through vessels that ...
Cached Medicine News:Health News:New 'seed' therapy helps pinpoint breast tumors with more accuracy 2Health News:UT Southwestern researcher named Howard Hughes Medical Institute investigator 2Health News:UT Southwestern researcher named Howard Hughes Medical Institute investigator 3Health News:ISS Recommends Hologic Stockholders Vote 'FOR' Merger With Cytyc 2Health News:ISS Recommends Hologic Stockholders Vote 'FOR' Merger With Cytyc 3Health News:ISS Recommends Hologic Stockholders Vote 'FOR' Merger With Cytyc 4Health News:Vocantas CallAssure provides hospitals with automated solution for post-discharge patient follow-up 2Health News:Vocantas CallAssure provides hospitals with automated solution for post-discharge patient follow-up 3Health News:New Resource Explains What Seniors Can Do if Medicare Denies Coverage of Their Medicines 2Health News:Highmark's Hospital Pay-for-Performance Program Demonstrates Impressive Results 2Health News:Highmark's Hospital Pay-for-Performance Program Demonstrates Impressive Results 3
Sony DSR-20MD is the right choice If you need digital recording capability. It accepts both s-video and composite inputs....
The VISERA Multi-Specialty Digital Imaging Platform is the world's first integrated system of digital rigid, deflectable tip and flexible videoscopes for use in operating room endosurgery as well as ...
... for clinical image management. Mediscan is ... management system derived from extensive experience ... to capture, organize, and distribute high ... with minimum effort. Can be connected ...
... probes feature response times in ... real-time monitoring of physiological events. ... measurements of pO2, blood perfusion ... from the same tissue site ...
Medicine Products: